You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMitoxantrone
Accession NumberDB01204  (APRD00371)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn anthracenedione-derived antineoplastic agent. [PubChem]
Structure
Thumb
Synonyms
1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
Mitoxantrona
Mitoxantrone
Mitoxantronum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mitoxantrone Injectionsolution2 mgintravenousFresenius Kabi Canada Ltd2007-12-03Not applicableCanada
Mitoxantrone Injectionsolution2 mgintravenousTeva Canada Limited2006-03-28Not applicableCanada
Mitoxantrone Injection USPsolution2 mgintravenousHospira Healthcare Corporation2001-12-03Not applicableCanada
Novantroneliquid2 mgintravenousWyeth Canada1996-12-022005-08-10Canada
Novantrone Inj 2mg/mlliquid2 mgintravenousLederle Cyanamid Canada Inc.1984-12-311997-08-14Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mitoxantroneinjection, solution, concentrate2 mg/mLintravenousHospira Worldwide, Inc.2006-04-11Not applicableUs
Mitoxantroneinjection, solution, concentrate2 mg/mLintravenousTeva Parenteral Medicines, Inc2006-04-11Not applicableUs
Mitoxantroneinjection, solution2 mg/mLintravenousFresenius Kabi USA, LLC2006-04-11Not applicableUs
Mitoxantroneinjection, solution, concentrate2 mg/mLintravenousTeva Parenteral Medicines, Inc2006-04-11Not applicableUs
Mitoxantroneinjection, solution, concentrate2 mg/mLintravenousTeva Parenteral Medicines, Inc2006-04-11Not applicableUs
Mitoxantrone Hydrochlorideinjection, solution2 mg/mLintravenousPfizer Laboratories Div Pfizer Inc.2012-12-12Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mitoxantrone hydrochloride
70476-82-3
Thumb
  • InChI Key: ZAHQPTJLOCWVPG-UHFFFAOYSA-N
  • Monoisotopic Mass: 516.154240126
  • Average Mass: 517.403
DBSALT000121
Categories
UNIIBZ114NVM5P
CAS number65271-80-9
WeightAverage: 444.4809
Monoisotopic: 444.200884648
Chemical FormulaC22H28N4O6
InChI KeyInChIKey=KKZJGLLVHKMTCM-UHFFFAOYSA-N
InChI
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
IUPAC Name
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione
SMILES
OCCNCCNC1=C2C(=O)C3=C(O)C=CC(O)=C3C(=O)C2=C(NCCNCCO)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anthraquinones. These are organic compounds containing either anthracene-9,10-quinone, 1,4-anthraquinone, or 1,2-anthraquinone.
KingdomOrganic compounds
Super ClassBenzenoids
ClassAnthracenes
Sub ClassAnthraquinones
Direct ParentAnthraquinones
Alternative Parents
Substituents
  • Anthraquinone
  • 9,10-anthraquinone
  • Aryl ketone
  • Hydroquinone
  • Secondary aliphatic/aromatic amine
  • Vinylogous amide
  • Vinylogous acid
  • Ketone
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
PharmacodynamicsMitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
Mechanism of actionMitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.
Related Articles
AbsorptionPoorly absorbed following oral administration
Volume of distribution
  • 1000 L/m2
Protein binding78%
Metabolism

Hepatic

Route of eliminationNot Available
Half life75 hours
Clearance
  • 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]
  • 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]
  • 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]
ToxicitySevere leukopenia with infection.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7557
Blood Brain Barrier-0.7979
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8417
P-glycoprotein inhibitor INon-inhibitor0.8674
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.7735
CYP450 2C9 substrateNon-substrate0.7907
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7013
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8544
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9211
Ames testAMES toxic0.9108
CarcinogenicityNon-carcinogens0.8742
BiodegradationNot ready biodegradable0.9727
Rat acute toxicity2.3061 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5839
hERG inhibition (predictor II)Inhibitor0.6894
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solution, concentrateintravenous2 mg/mL
Injection, solutionintravenous2 mg/mL
Solutionintravenous2 mg
Liquidintravenous2 mg
Prices
Unit descriptionCostUnit
Novantrone 2 mg/ml Concentrate 10ml Vial1649.32USD vial
Novantrone 2 mg/ml vial158.59USD ml
Mitoxantrone 20 mg/10 ml vial42.0USD ml
Mitoxantrone 25 mg/12.5 ml vial37.5USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
logP-3.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.734 mg/mLALOGPS
logP0.91ALOGPS
logP1.19ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)9.78ChemAxon
pKa (Strongest Basic)9.08ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area163.18 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity123.53 m3·mol-1ChemAxon
Polarizability48.49 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US4197249
General References
  1. Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74. [PubMed:16750460 ]
External Links
ATC CodesL01DB07
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (1.3 MB)
MSDSDownload (53.2 KB)
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Mitoxantrone.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Mitoxantrone.
AcetaminophenThe serum concentration of Mitoxantrone can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mitoxantrone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Mitoxantrone.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Mitoxantrone.
AfatinibThe serum concentration of Mitoxantrone can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Mitoxantrone can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Mitoxantrone can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Mitoxantrone.
AmantadineThe serum concentration of Mitoxantrone can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Mitoxantrone.
Aminohippuric acidThe serum concentration of Mitoxantrone can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Mitoxantrone.
AmitriptylineThe serum concentration of Mitoxantrone can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Mitoxantrone can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Mitoxantrone can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Mitoxantrone can be increased when it is combined with Amsacrine.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Mitoxantrone.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Mitoxantrone.
AstemizoleThe serum concentration of Mitoxantrone can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Mitoxantrone.
AtazanavirThe serum concentration of Mitoxantrone can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Mitoxantrone.
AtenololThe serum concentration of Mitoxantrone can be increased when it is combined with Atenolol.
AtorvastatinThe serum concentration of Mitoxantrone can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Mitoxantrone.
AzelastineThe serum concentration of Mitoxantrone can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Mitoxantrone can be increased when it is combined with Azithromycin.
BenzocaineThe serum concentration of Mitoxantrone can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Mitoxantrone can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Mitoxantrone.
BevacizumabBevacizumab may increase the cardiotoxic activities of Mitoxantrone.
BiperidenThe serum concentration of Mitoxantrone can be increased when it is combined with Biperiden.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Mitoxantrone.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Mitoxantrone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mitoxantrone.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Mitoxantrone.
BromocriptineThe serum concentration of Mitoxantrone can be increased when it is combined with Bromocriptine.
BuprenorphineThe serum concentration of Mitoxantrone can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Mitoxantrone can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Mitoxantrone.
CabazitaxelThe serum concentration of Mitoxantrone can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Mitoxantrone.
CaffeineThe serum concentration of Mitoxantrone can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Mitoxantrone.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Mitoxantrone.
CanagliflozinThe serum concentration of Mitoxantrone can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Mitoxantrone can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Mitoxantrone can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Mitoxantrone can be decreased when it is combined with Carbamazepine.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Mitoxantrone.
CarvedilolThe serum concentration of Mitoxantrone can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Mitoxantrone can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Mitoxantrone.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Mitoxantrone.
ChloroquineThe serum concentration of Mitoxantrone can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Mitoxantrone.
ChlorpromazineThe serum concentration of Mitoxantrone can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Mitoxantrone can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Mitoxantrone can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Mitoxantrone can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Mitoxantrone can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Mitoxantrone can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Mitoxantrone can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Mitoxantrone.
CiprofloxacinThe serum concentration of Mitoxantrone can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Mitoxantrone.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Mitoxantrone.
CitalopramThe serum concentration of Mitoxantrone can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Mitoxantrone.
ClarithromycinThe serum concentration of Mitoxantrone can be increased when it is combined with Clarithromycin.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Mitoxantrone.
ClofazimineThe serum concentration of Mitoxantrone can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Mitoxantrone.
ClomipramineThe serum concentration of Mitoxantrone can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Mitoxantrone.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Mitoxantrone.
ClotrimazoleThe serum concentration of Mitoxantrone can be decreased when it is combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Clozapine.
CobicistatThe serum concentration of Mitoxantrone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Mitoxantrone.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Mitoxantrone.
ColchicineThe serum concentration of Mitoxantrone can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Mitoxantrone can be increased when it is combined with Colforsin.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Mitoxantrone.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Mitoxantrone.
CrizotinibThe serum concentration of Mitoxantrone can be increased when it is combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mitoxantrone.
CyclosporineThe serum concentration of Mitoxantrone can be decreased when it is combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Mitoxantrone can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Mitoxantrone.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Mitoxantrone.
DaclatasvirThe serum concentration of Mitoxantrone can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Mitoxantrone.
DactinomycinThe serum concentration of Mitoxantrone can be increased when it is combined with Dactinomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Mitoxantrone.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Mitoxantrone.
DasatinibThe serum concentration of Mitoxantrone can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Mitoxantrone.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Mitoxantrone.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mitoxantrone.
DesipramineThe serum concentration of Mitoxantrone can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mitoxantrone.
DesloratadineThe serum concentration of Mitoxantrone can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Mitoxantrone can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Mitoxantrone can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Mitoxantrone.
DiclofenacThe serum concentration of Mitoxantrone can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Mitoxantrone.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mitoxantrone.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Mitoxantrone.
DigoxinDigoxin may decrease the cardiotoxic activities of Mitoxantrone.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Mitoxantrone.
DihydroergotamineThe serum concentration of Mitoxantrone can be increased when it is combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Mitoxantrone.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Mitoxantrone.
DiltiazemThe serum concentration of Mitoxantrone can be increased when it is combined with Diltiazem.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Mitoxantrone.
DipyridamoleThe serum concentration of Mitoxantrone can be increased when it is combined with Dipyridamole.
DisulfiramThe metabolism of Mitoxantrone can be decreased when combined with Disulfiram.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Mitoxantrone.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoxantrone.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Mitoxantrone.
DoxazosinThe serum concentration of Mitoxantrone can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Mitoxantrone can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Mitoxantrone.
DronabinolThe serum concentration of Mitoxantrone can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Mitoxantrone can be increased when it is combined with Dronedarone.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Mitoxantrone.
ElbasvirThe serum concentration of Mitoxantrone can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Mitoxantrone.
EltrombopagThe serum concentration of Mitoxantrone can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Mitoxantrone can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Mitoxantrone can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Mitoxantrone.
ErgonovineThe serum concentration of Mitoxantrone can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Mitoxantrone can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Mitoxantrone.
ErythromycinThe serum concentration of Mitoxantrone can be decreased when it is combined with Erythromycin.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Mitoxantrone.
EstramustineThe serum concentration of Mitoxantrone can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Mitoxantrone.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Mitoxantrone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mitoxantrone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Mitoxantrone.
EtoposideThe serum concentration of Mitoxantrone can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Mitoxantrone can be increased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Mitoxantrone.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Mitoxantrone.
FelodipineThe serum concentration of Mitoxantrone can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Mitoxantrone can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Mitoxantrone.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Mitoxantrone.
FexofenadineThe serum concentration of Mitoxantrone can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Mitoxantrone.
FidaxomicinThe serum concentration of Mitoxantrone can be increased when it is combined with Fidaxomicin.
FingolimodMitoxantrone may increase the immunosuppressive activities of Fingolimod.
FluconazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Fluconazole.
FluoxetineThe serum concentration of Mitoxantrone can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Mitoxantrone can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Mitoxantrone can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Mitoxantrone can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Mitoxantrone.
FluvoxamineThe serum concentration of Mitoxantrone can be increased when it is combined with Fluvoxamine.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Mitoxantrone.
GefitinibThe serum concentration of Mitoxantrone can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Mitoxantrone.
GenisteinThe serum concentration of Mitoxantrone can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Mitoxantrone can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Mitoxantrone can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Mitoxantrone can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Mitoxantrone.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Mitoxantrone.
GrepafloxacinThe serum concentration of Mitoxantrone can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Mitoxantrone.
HaloperidolThe serum concentration of Mitoxantrone can be increased when it is combined with Haloperidol.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Mitoxantrone.
HydrocortisoneThe serum concentration of Mitoxantrone can be increased when it is combined with Hydrocortisone.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Mitoxantrone.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Mitoxantrone.
IdelalisibThe serum concentration of Mitoxantrone can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Mitoxantrone.
ImatinibThe serum concentration of Mitoxantrone can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Mitoxantrone.
ImipramineThe serum concentration of Mitoxantrone can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Mitoxantrone.
IndinavirThe serum concentration of Mitoxantrone can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Mitoxantrone.
IndomethacinThe serum concentration of Mitoxantrone can be increased when it is combined with Indomethacin.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Mitoxantrone.
IsavuconazoniumThe serum concentration of Mitoxantrone can be increased when it is combined with Isavuconazonium.
IsoniazidThe metabolism of Mitoxantrone can be decreased when combined with Isoniazid.
ItraconazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Mitoxantrone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Mitoxantrone.
IvermectinThe serum concentration of Mitoxantrone can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Mitoxantrone can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Mitoxantrone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Mitoxantrone.
KetoconazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Mitoxantrone.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Mitoxantrone.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Mitoxantrone.
LansoprazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Mitoxantrone can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Mitoxantrone.
LeflunomideThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Mitoxantrone.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Mitoxantrone.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Mitoxantrone.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Mitoxantrone.
LevofloxacinThe serum concentration of Mitoxantrone can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Mitoxantrone.
LevothyroxineThe serum concentration of Mitoxantrone can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Mitoxantrone can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Mitoxantrone.
LiothyronineThe serum concentration of Mitoxantrone can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Mitoxantrone can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Mitoxantrone can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Mitoxantrone can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Mitoxantrone.
LoperamideThe serum concentration of Mitoxantrone can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Mitoxantrone can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Mitoxantrone can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Mitoxantrone.
LosartanThe serum concentration of Mitoxantrone can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Mitoxantrone can be increased when it is combined with Lovastatin.
LumacaftorThe serum concentration of Mitoxantrone can be decreased when it is combined with Lumacaftor.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Mitoxantrone.
MaprotilineThe serum concentration of Mitoxantrone can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Mitoxantrone can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Mitoxantrone can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Mitoxantrone can be increased when it is combined with Meprobamate.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Mitoxantrone.
MethadoneThe serum concentration of Mitoxantrone can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Mitoxantrone.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Mitoxantrone.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Mitoxantrone.
MetoprololThe serum concentration of Mitoxantrone can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Mitoxantrone can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Mitoxantrone can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Mitoxantrone can be decreased when it is combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Mitoxantrone.
MitomycinThe serum concentration of Mitoxantrone can be increased when it is combined with Mitomycin.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Mitoxantrone.
MorphineThe serum concentration of Mitoxantrone can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Mitoxantrone.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Mitoxantrone.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Mitoxantrone.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Mitoxantrone.
NaltrexoneThe serum concentration of Mitoxantrone can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Mitoxantrone can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Natalizumab.
NefazodoneThe serum concentration of Mitoxantrone can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Mitoxantrone can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Mitoxantrone can be increased when it is combined with Neostigmine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Mitoxantrone.
NicardipineThe serum concentration of Mitoxantrone can be increased when it is combined with Nicardipine.
NicotineThe metabolism of Mitoxantrone can be decreased when combined with Nicotine.
NifedipineThe serum concentration of Mitoxantrone can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Mitoxantrone.
NilotinibThe serum concentration of Mitoxantrone can be increased when it is combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Mitoxantrone.
NisoldipineThe serum concentration of Mitoxantrone can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Mitoxantrone can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Mitoxantrone can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Mitoxantrone.
NorethisteroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Norethisterone.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Mitoxantrone.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Mitoxantrone.
OmeprazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Mitoxantrone.
OuabainOuabain may decrease the cardiotoxic activities of Mitoxantrone.
P-NitrophenolThe serum concentration of Mitoxantrone can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Mitoxantrone.
PaclitaxelThe serum concentration of Mitoxantrone can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Mitoxantrone can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Mitoxantrone.
PantoprazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Mitoxantrone can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Mitoxantrone.
PerindoprilThe serum concentration of Mitoxantrone can be increased when it is combined with Perindopril.
PhenobarbitalThe serum concentration of Mitoxantrone can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Mitoxantrone.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mitoxantrone.
PimozideThe serum concentration of Mitoxantrone can be increased when it is combined with Pimozide.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Mitoxantrone.
Platelet Activating FactorThe serum concentration of Mitoxantrone can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Mitoxantrone.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Mitoxantrone.
PonatinibThe serum concentration of Mitoxantrone can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Mitoxantrone can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Mitoxantrone.
PravastatinThe serum concentration of Mitoxantrone can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Mitoxantrone.
PrazosinThe serum concentration of Mitoxantrone can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Mitoxantrone.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Mitoxantrone.
PrednisoneThe serum concentration of Mitoxantrone can be increased when it is combined with Prednisone.
ProbenecidThe serum concentration of Mitoxantrone can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Mitoxantrone can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Mitoxantrone can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Mitoxantrone.
PropranololThe serum concentration of Mitoxantrone can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Mitoxantrone can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Mitoxantrone.
QuercetinThe serum concentration of Mitoxantrone can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Mitoxantrone.
QuinacrineThe serum concentration of Mitoxantrone can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Mitoxantrone.
QuinidineThe serum concentration of Mitoxantrone can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Mitoxantrone.
QuinineThe serum concentration of Mitoxantrone can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Rabies vaccine.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Mitoxantrone.
RanitidineThe serum concentration of Mitoxantrone can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Mitoxantrone.
ReboxetineThe serum concentration of Mitoxantrone can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Mitoxantrone can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Mitoxantrone can be decreased when it is combined with Reserpine.
RifampicinThe serum concentration of Mitoxantrone can be decreased when it is combined with Rifampicin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Mitoxantrone.
RilpivirineThe serum concentration of Mitoxantrone can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Mitoxantrone.
RitonavirThe serum concentration of Mitoxantrone can be decreased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Mitoxantrone.
RoflumilastRoflumilast may increase the immunosuppressive activities of Mitoxantrone.
RolapitantThe serum concentration of Mitoxantrone can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Mitoxantrone.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Mitoxantrone.
SaquinavirThe serum concentration of Mitoxantrone can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Mitoxantrone can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Mitoxantrone can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Mitoxantrone.
SertralineThe serum concentration of Mitoxantrone can be increased when it is combined with Sertraline.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Mitoxantrone.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Mitoxantrone.
SimeprevirThe serum concentration of Mitoxantrone can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Mitoxantrone can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mitoxantrone.
SirolimusThe serum concentration of Mitoxantrone can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Mitoxantrone.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Mitoxantrone.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Mitoxantrone.
SorafenibThe serum concentration of Mitoxantrone can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Mitoxantrone.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Mitoxantrone.
SpironolactoneThe serum concentration of Mitoxantrone can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Mitoxantrone can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Mitoxantrone can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Mitoxantrone can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Mitoxantrone can be increased when it is combined with Sulfinpyrazone.
SumatriptanThe serum concentration of Mitoxantrone can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Mitoxantrone can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Mitoxantrone can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Mitoxantrone.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Mitoxantrone.
TamoxifenThe serum concentration of Mitoxantrone can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Mitoxantrone.
Taurocholic AcidThe serum concentration of Mitoxantrone can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Mitoxantrone.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Mitoxantrone.
TelmisartanThe serum concentration of Mitoxantrone can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Mitoxantrone.
TemsirolimusThe serum concentration of Mitoxantrone can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Mitoxantrone can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Mitoxantrone can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Mitoxantrone can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Mitoxantrone can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Mitoxantrone can be increased when it is combined with Testosterone.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Mitoxantrone.
TicagrelorThe serum concentration of Mitoxantrone can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Mitoxantrone can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Mitoxantrone.
TofacitinibMitoxantrone may increase the immunosuppressive activities of Tofacitinib.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Mitoxantrone.
TolvaptanThe serum concentration of Mitoxantrone can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Mitoxantrone.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Mitoxantrone.
TrastuzumabTrastuzumab may increase the neutropenic activities of Mitoxantrone.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Mitoxantrone.
TrazodoneThe serum concentration of Mitoxantrone can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Mitoxantrone can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Mitoxantrone can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Mitoxantrone can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Mitoxantrone can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Mitoxantrone can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Mitoxantrone.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Mitoxantrone.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Mitoxantrone.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Mitoxantrone.
VenlafaxineThe serum concentration of Mitoxantrone can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Mitoxantrone can be decreased when it is combined with Verapamil.
VinblastineThe serum concentration of Mitoxantrone can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Mitoxantrone.
VincristineThe serum concentration of Mitoxantrone can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Mitoxantrone can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Mitoxantrone.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Mitoxantrone.
ZimelidineThe serum concentration of Mitoxantrone can be increased when it is combined with Zimelidine.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Mazerski J, Martelli S, Borowski E: The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: molecular dynamics simulations. Acta Biochim Pol. 1998;45(1):1-11. [PubMed:9701490 ]
  2. Hajihassan Z, Rabbani-Chadegani A: Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins. J Biomed Sci. 2009 Mar 11;16:31. doi: 10.1186/1423-0127-16-31. [PubMed:19284573 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Takeda K, Shinohara K, Kameda N, Ariyoshi K: A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide. Int J Hematol. 1998 Feb;67(2):179-86. [PubMed:9631585 ]
  3. McPherson JP, Deffie AM, Jones NR, Brown GA, Deuchars KL, Goldenberg GJ: Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha. Anticancer Res. 1997 Nov-Dec;17(6D):4243-52. [PubMed:9494516 ]
  4. Wang H, Mao Y, Zhou N, Hu T, Hsieh TS, Liu LF: Atp-bound topoisomerase ii as a target for antitumor drugs. J Biol Chem. 2001 May 11;276(19):15990-5. Epub 2001 Feb 23. [PubMed:11278845 ]
  5. Satherley K, de Souza L, Neale MH, Alexander RA, Myatt N, Foss AJ, Hungerford JL, Hickson ID, Cree IA: Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma. J Pathol. 2000 Oct;192(2):174-81. [PubMed:11004693 ]
  6. Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, Liu LF: Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry. 1999 Aug 17;38(33):10793-800. [PubMed:10451375 ]
  7. Ko MW, Tamhankar MA, Volpe NJ, Porter D, McGrath C, Galetta SL: Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. J Neurol Sci. 2008 Oct 15;273(1-2):144-7. doi: 10.1016/j.jns.2008.06.028. Epub 2008 Aug 6. [PubMed:18687447 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schrenk D, Michalke A, Gant TW, Brown PC, Silverman JA, Thorgeirsson SS: Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone. Biochem Pharmacol. 1996 Nov 8;52(9):1453-60. [PubMed:8937457 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  3. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci. 2004 Jan;21(1):69-75. [PubMed:14706813 ]
  4. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ: Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505. Epub 2006 Jan 24. [PubMed:16434618 ]
  2. Diah SK, Smitherman PK, Aldridge J, Volk EL, Schneider E, Townsend AJ, Morrow CS: Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res. 2001 Jul 15;61(14):5461-7. [PubMed:11454692 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Volk EL, Schneider E: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43. [PubMed:14500392 ]
  2. Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9. doi: 10.3109/01480540903390000. [PubMed:20307139 ]
  3. Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ: Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505. Epub 2006 Jan 24. [PubMed:16434618 ]
  4. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 2000 Jun;113 ( Pt 11):2011-21. [PubMed:10806112 ]
  5. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72. [PubMed:12488537 ]
  6. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003 Jan;2(1):105-12. [PubMed:12533678 ]
  7. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999 Sep 15;59(18):4559-63. [PubMed:10493507 ]
  8. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380 ]
  9. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197 ]
  10. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y: Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int J Cancer. 2003 Dec 10;107(5):757-63. [PubMed:14566825 ]
  11. Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD: Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol. 2003 Dec;64(6):1452-62. [PubMed:14645676 ]
  12. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44. [PubMed:12649196 ]
  13. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH: The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999 Sep 1;59(17):4237-41. [PubMed:10485464 ]
  14. An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42. doi: 10.1517/17425250903228834. [PubMed:19708828 ]
  15. Paturi DK, Kwatra D, Ananthula HK, Pal D, Mitra AK: Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3). Int J Pharm. 2010 Jan 15;384(1-2):32-8. doi: 10.1016/j.ijpharm.2009.09.037. Epub 2009 Sep 25. [PubMed:19782742 ]
  16. Ma Y, Wink M: The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9. doi: 10.1002/ptr.2860. [PubMed:19548284 ]
  17. Mahringer A, Delzer J, Fricker G: A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2). Eur J Pharm Biopharm. 2009 Aug;72(3):605-13. doi: 10.1016/j.ejpb.2009.01.010. [PubMed:19572416 ]
  18. Nicolle E, Boccard J, Guilet D, Dijoux-Franca MG, Zelefac F, Macalou S, Grosselin J, Schmidt J, Carrupt PA, Di Pietro A, Boumendjel A: Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur J Pharm Sci. 2009 Aug 12;38(1):39-46. doi: 10.1016/j.ejps.2009.05.012. Epub 2009 Jun 6. [PubMed:19501160 ]
  19. Jani M, Szabo P, Kis E, Molnar E, Glavinas H, Krajcsi P: Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. Biol Pharm Bull. 2009 Mar;32(3):497-9. [PubMed:19252303 ]
  20. Karla PK, Earla R, Boddu SH, Johnston TP, Pal D, Mitra A: Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr Eye Res. 2009 Jan;34(1):1-9. doi: 10.1080/02713680802518251. [PubMed:19172464 ]
  21. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  22. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
  23. Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F, Chen ZS: The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep. 2009 Feb;21(2):483-9. [PubMed:19148526 ]
  24. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999 Mar 3;91(5):429-33. [PubMed:10070941 ]
  25. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, Bates SE: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999 Dec 1;59(23):5938-46. [PubMed:10606239 ]
  26. Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE, Schneider E: The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun. 2000 Apr 29;271(1):42-6. [PubMed:10777678 ]
  27. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst. 2000 Oct 18;92(20):1651-6. [PubMed:11036110 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23